Get the Stockscreener App
0.6467
1.48%
0.0096
Scynexis Inc stock is traded at $0.6467, with a volume of 127.38K.
It is up +1.48% in the last 24 hours and down -1.39% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$0.6371
Open:
$0.635
24h Volume:
127.38K
Relative Volume:
0.25
Market Cap:
$26.92M
Revenue:
$3.26M
Net Income/Loss:
$-19.52M
P/E Ratio:
-1.6168
EPS:
-0.4
Net Cash Flow:
$-24.10M
1W Performance:
+6.75%
1M Performance:
-1.39%
6M Performance:
-11.61%
1Y Performance:
-51.02%
1-Day Range:
$0.6312
$0.655
1-Week Range:
$0.604
$0.655
52-Week Range:
$0.565
$1.3484
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.6414 | 26.74M | 3.26M | -19.52M | -24.10M | -0.40 |
|
ZTS
Zoetis Inc
|
129.44 | 57.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.80 | 49.57B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.06 | 35.57B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
502.89 | 21.08B | 3.08B | 1.24B | 1.07B | 25.61 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
Why SCYNEXIS Inc. stock is trending among retail tradersMarket Profile Overview & High Profit Trading Signals - bollywoodhelpline.com
Portfolio Update: How SCYNEXIS Inc stock compares to industry benchmarksJuly 2025 Highlights & Free Safe Capital Growth Stock Tips - moha.gov.vn
SCYNEXIS granted Nasdaq extension to regain bid price compliance - MSN
What analysts say about SCYNEXIS Inc 135A stockFundamental Strength Indicators & Build Wealth With Expert Timing Advice - earlytimes.in
Scynexis receives 180-day extension from Nasdaq to meet listing requirements - Investing.com
Scynexis granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement - marketscreener.com
SCYNEXIS, Inc. Receives 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Quiver Quantitative
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Earnings Report: Why SCYNEXIS Inc. stock is trending among retail tradersAnalyst Downgrade & Long Hold Capital Preservation Plans - Улправда
SCYNEXIS Earnings Notes - Trefis
Is SCYNEXIS Inc. stock trading at a premium valuationEarnings Risk Summary & Reliable Volume Spike Alerts - Улправда
Shorts Report: How SCYNEXIS Inc. (135A) stock compares with tech leadersEarnings Summary Report & Safe Entry Momentum Stock Tips - moha.gov.vn
Why SCYNEXIS Inc. (135A) stock is listed among top recommendationsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - Улправда
SCYNEXIS halts phase 3 MARIO trial, raising new questions for ibrexafungerp’s growth path - MSN
SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path - TipRanks
Will SCYNEXIS Inc. stock deliver better than expected guidance2025 Key Lessons & Advanced Swing Trade Entry Plans - DonanımHaber
Can SCYNEXIS Inc. stock continue upward trendEarnings Summary Report & Long-Term Growth Stock Strategies - Улправда
How SCYNEXIS Inc. (135A) stock compares with tech leadersJuly 2025 Momentum & Verified Stock Trade Ideas - Bölüm Sonu Canavarı
Why SCYNEXIS Inc. stock is a must watch in 2025Market Trend Review & Fast Momentum Stock Entry Tips - Улправда
Nasdaq Moves: Why SCYNEXIS Inc. stock is a must watch in 2025Weekly Stock Recap & AI Powered Market Trend Analysis - Улправда
Is SCYNEXIS Inc. stock a contrarian buy2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
What insider purchases suggest about SCYNEXIS Inc. (135A) stockJuly 2025 Macro Moves & AI Enhanced Trading Alerts - ulpravda.ru
Revenue per share of SCYNEXIS, Inc. – BER:135A - TradingView — Track All Markets
SCYNEXIS (NASDAQ:SCYX) versus NewAmsterdam Pharma (NASDAQ:NAMS) Head to Head Analysis - Defense World
Can SCYNEXIS Stock Hold Up When Markets Turn? - Trefis
Can SCYNEXIS Inc. stock surprise with earnings upsideVolume Spike & Real-Time Price Movement Reports - Newser
Why SCYNEXIS Inc. (135A) stock stays resilientWeekly Stock Report & Smart Swing Trading Techniques - Newser
How SCYNEXIS Inc. stock trades before earnings2025 Breakouts & Breakdowns & Low Drawdown Momentum Ideas - Newser
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
What is the fair value of SCYNEXIS Inc. stock nowEarnings Performance Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is SCYNEXIS Inc. (135A) stock considered safe havenDollar Strength & Low Risk Investment Opportunities - Newser
Free cash flow per share of SCYNEXIS, Inc. – LSE:0L49 - TradingView
Working capital per share of SCYNEXIS, Inc. – LSE:0L49 - TradingView
Macro Review: Why SCYNEXIS Inc. stock is trending among retail tradersJuly 2025 Retail & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Is SCYNEXIS Inc a good long term investmentGrowth Stock Opportunities & Exceptional Return Growth - earlytimes.in
It is Poised to be a Bull Market for Scynexis Inc (SCYX) - Setenews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Investors in cash trouble should check out Scynexis Inc (SCYX) - Setenews
Will SCYNEXIS Inc. (135A) stock outperform foreign stocksJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration - MSN
Analyzing recovery setups for SCYNEXIS Inc. investorsFed Meeting & Fast Gain Stock Trading Tips - newser.com
Will SCYNEXIS Inc. stock recover faster than peersJuly 2025 Update & Technical Pattern Alert System - newser.com
Scynexis Transfers Brexafemme New Drug Application to GSK - MarketScreener
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):